Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Corepharma LLC
WARNING LETTER
•Corepharma LLC•January 20, 2010

Corepharma LLC – FDA Warning Letter, Jan 20, 2010

Record Details

An FDA inspection of CorePharma, LLC's pharmaceutical manufacturing facility in Middlesex, New Jersey, from November 2009 to January 2010, identified significant Current Good Manufacturing Practice (CGMP) violations under 21 CFR Parts 210 and 211, rendering drug products adulterated. The firm's February 2010 response was deemed inadequate. Key violations included failure to reject drug products not meeting specifications (e.g., Benzphetamine HCl tablets with coating defects), inadequate investigation of batch failures and Out-of-Specification (OOS) results without extending investigations or determining root causes (e.g., Pilocarpine HCl thickness, Pyridostigmine Bromide black spots, Ropinirole HCl coating defects, delayed action on crushed tablets). The Quality Control Unit (QCU) failed to follow written procedures, such as assigning target completion dates for corrective actions, a repeat observation. The firm also failed to establish procedures to monitor and validate manufacturing processes and reject non-conforming in-process material (e.g., Ursodiol capsule fill weight/dissolution, Ropinirole HCl coating issues). Additionally, CorePharma failed to adhere to its stability testing program and provide adequate systems to control contaminants during production, as evidenced by manufacturing near an open construction area. Repeat observations and concerns about the QCU's effectiveness were highlighted. CorePharma must promptly correct these violations, provide a written response within fifteen working days detailing corrective actions, and address recurrence prevention. Failure to comply may result in legal action, including seizure and injunction, and impact approvals for export certificates or pending drug applications.

Company
Corepharma LLC
Inspection date
January 20, 2010
Product type
Drugs
Office
New Jersey District Office
People
  • Diana Amador-Toro (District Director)
  • Andrew Ciaccia (Compliance Officer)
View Company Profile

ID · cc9fe459-1a9b-4214-895a-dce33a73e958

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.165(f)21 CFR 211.19221 CFR 211.22(d)21 CFR 211.110(a)21 CFR 211.110(c)21 CFR 211.166(a)21 CFR 211.46(c)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Corepharma LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.